PUBLISHER: DataM Intelligence | PRODUCT CODE: 1083002
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1083002
Global POEMS Syndrome Market - 2022-2029
Market - Overview
The global POEMS syndrome market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome is a blood disorder that affects several body systems. Abnormal plasma cells produce excessive quantities of antibody proteins to collect in the blood in this uncommon illness. A high concentration of these proteins in the blood can harm nerves and cause organ systems to malfunction. POEMS syndrome does not have conventional treatment. Radiation therapy, chemotherapy, and hematopoietic cell transplantation are alternatives for people with POEMS syndrome.
Market Dynamics
Innovation in the treatment of POEMS Syndrome is expected to drive market growth.
POEMS treatment, like multiple myeloma treatment, aims to eradicate the offending plasma cell clone. High-dose melphalan followed by autologous hematopoietic cell transplant (HCT) provides the best long-term results for eligible individuals. Moreover, patients who cannot tolerate HCT are given plasma cell-directed treatment. Immunomodulatory medicines in various combinations include lenalidomide, proteasome inhibitors like bortezomib, dexamethasone, and cyclophosphamide. Therefore, it has increased the demand for the drug. Thus, from the above statements, the market is expected to drive in the forecast period.
Restraint:
Lack of awareness of the disease among the population, side effects of the drugs and restricted access to necessary healthcare facilities are some factors the market is expected to hamper in the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic's management had an indirect impact on major diseases. In reality, fear of the epidemic's catastrophe is causing many sufferers to put off seeking treatment. Aside from chronic patient monitoring, the practitioner's primary goal is to detect emergency circumstances. The POEMS syndrome with plasmacytoma lytic bone lesion is still a rare occurrence. Radiotherapy is advised as a treatment strategy with variable success in patients with less than three isolated bone plasmacytomas.
In contrast, there is a delay in treating POEMS Syndrome as there is contact between the patient and the doctor. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.
Segment Analysis
Chemotherapy segment is expected to hold the largest market share in POEMS syndrome market
The chemotherapy segment is expected to dominate in 2021. The segment is benefited because high-dose chemotherapy with ASCT can achieve excellent clinical responses, with a significant improvement of neuropathy, complete hematologic response (CRH) in 60% of POEMS syndrome patients, and complete VEGF response (CRV) in 50%. For instance, Melphalan is an alkylation agent commonly used to treat plasma diseases such as myeloma and amyloidosis. MDex (Melphalan plus dexamethasone) produced a 100% neurological response. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Geographical Analysis
North America region holds the largest market share in the global POEMS syndrome market
In 2021, North America accounted for the highest revenue share. The advancement in the diagnosis of the disease, well-established clinical facilities, and clinical trials conducted for the treatment and product launches by the market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Patients with POEMS usually have a long-term, progressively deteriorating, length-dependent, and demyelinating peripheral neuropathy. While the syndrome is comparable to the more frequent CIDP, it differs in several ways. POEMS patients had more axonal degeneration, neuropathic pain, and lower-limb atrophy than CIDP patients, although cranial nerve involvement and dysautonomia are significantly less common. A crucial screening technique for diagnosing POEMS syndrome is serum or urine immunofixation electrophoresis. The symptoms listed above, along with a lambda light chain-restricted immunofixation electrophoresis profile, strongly imply a diagnosis.
Additionally, Geneyork Pharmaceutical, a privately held specialty pharmaceutical company that develops, contract manufactures, and sells finished pharmaceutical products, launched the commercial shipment of Generic Deltasone (Prednisone) Tablets in the United States on February 2, 2020, in collaboration with Lannett Company, Geneyork's U.S. distribution and marketing partner. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Competitive Landscape
Major key players in the POEMS syndrome market are Pfizer, Inc., Bristol-Myers Squibb Company, Baxter, Genentech USA, Inc., Takeda Pharmaceuticals U.S.A., Inc., Oncopeptides AB. Acrotech Biopharma, LLC., LGM PHARMA , Jubilant Cadista Pharmaceuticals Inc.
Bristol-Myers Squibb Company:
Overview:
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company. It is headquartered in New York City. The company has advancements in oncology, hematology, immunology and cardiovascular disease. It is dedicated to helping patients prevail over serious diseases through its diverse and promising pipelines and new scientific platforms. Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines. Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs is a subsidiary of Bristol Myers Squibb.
Product Portfolio:
REVLIMID (lenalidomide): Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines.
Why Purchase the Report?
Visualize the composition of the POEMS syndrome market segmentation by diagnosis type, treatment type, end user, distribution channel, and region highlighting the key commercial assets and players.
Identify commercial opportunities in POEMS syndrome market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of POEMS syndrome market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global POEMS syndrome market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.
Target Audience
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
- 3.1. Market Snippet by Diagnosis Type
- 3.2. Market Snippet by Treatment Type
- 3.3. Market Snippet by End user
- 3.4. Market Snippet by Distribution channel
- 3.5. Market Snippet by Region
4. Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Innovation in the treatment of POEMS Syndrome is expected to drive market growth.
- 4.1.2. Restraints:
- 4.1.2.1. Lack of awareness of the disease among the population is expected to hamper in the forecast period.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Supply Chain Analysis
- 5.2. Pricing Analysis
- 5.3. Unmet Needs
6. COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Diagnosis Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 7.1.2. Market Attractiveness Index, By Diagnosis Type Segment
- 7.2. Electromyelogram (EMG)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. Blood and/or urine tests
- 7.4. Imaging
- 7.4.1. X-ray
- 7.4.2. CT scan
- 7.4.3. Others
- 7.5. Physical exam
- 7.6. Biopsy
- 7.7. Others
8. By Treatment Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.1.2. Market Attractiveness Index, By Treatment Type Segment
- 8.2. Chemotherapy*
- 8.2.1. Cyclophosphamide
- 8.2.2. Pepaxto (melphalan flufenamide
- 8.2.3. Others
- 8.2.4. Introduction
- 8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3. Radiation therapy
- 8.4. Physical therapy
- 8.5. Others
9. By End user
- 9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 9.1.2. Market Attractiveness Index, By End user Segment
- 9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.3. Diagnostic Centers
- 9.4. Ambulatory Surgical Centers
- 9.5. Others
10. By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
- 10.2. Hospital Pharmacies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies
- 10.5. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. U.K.
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
- 12.1. Key Developments and Strategies
- 12.2. Company Share Analysis
- 12.3. Product Benchmarking
- 12.4. List of Key Companies to Watch
13. Company Profiles
- 13.1. Pfizer Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
- 13.2. Bristol-Myers Squibb Company
- 13.3. Baxter
- 13.4. Genentech USA, Inc.
- 13.5. Takeda Pharmaceuticals U.S.A., Inc.
- 13.6. Oncopeptides AB
- 13.7. Acrotech Biopharma, LLC.
- 13.8. LGM PHARMA
- 13.9. Jubilant Cadista Pharmaceuticals Inc.
LIST NOT EXHAUSTIVE
14. Global POEMS Syndrome Market - DataM
- 14.1. Appendix
- 14.2. About Us and Applications
- 14.3. Contact Us
